@FierceBiotech: Takeda uprooting its U.S. vaccines operations, joining the R&D migration to Boston. Report | Follow @FierceBiotech
@JohnCFierce: Trending: With a crucial CAR-T trial looming for Cellectis, a confident André Choulika is laying it all on the line. More | Follow @JohnCFierce
@DamianFierce: $FOLD plans to market the Fabry drug migalastat as Galafold. Release | Follow @DamianFierce
> Dutch biotech Kiadis Pharma is planning to go public on the Amsterdam and Brussels stock exchanges, raising cash for its pipeline of cancer treatments. News
> Amicus Therapeutics ($FOLD) has submitted migalastat, a treatment for the rare Fabry disease, for European approval. The company expects to file the drug with the FDA in the second half of the year. More (PDF)
> Cellectis ($CLLS) has recruited the cancer experts at Weill Cornell Medical College to accelerate the development of its lead CAR-T candidate for acute myelogenous leukemia. Release
> Merck ($MRK) has extended its collaboration with Agenus ($AGEN), working to develop new checkpoint inhibitors for cancer. Item
Medical Device News
@FierceMedDev: Merck teams up with NanoString to find genes that predict response to Keytruda. FierceDiagnostics article | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Ishrak plays up four-point integration plan during Medtronic's earnings call. Story | Follow @VarunSaxena2
@EmilyWFierce: LabCorp strikes liquid biopsy deal with Sysmex for cancer drug development. FierceDiagnostics article | Follow @EmilyWFierce
> FDA clears first 'smart' spirometer, enabling continuous tracking of lung function via tablet. Story
> Former Stryker R&D exec spins off new company with novel bone adhesive. Report
> Aussie startup gets $11.5M to market FDA-cleared, wearable Parkinson's disease tracker. Article
Pharma News
@FiercePharma: India's pharmacies launch pre-emptive protest to online drug sales. FiercePharmaAsia article | Follow @FiercePharma
@EricPFierce: India's Wockhardt believes FDA issues at 2 key plants can be resolved sometime next year. Story from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: It's Stanley Cup Finals day!! And I just slipped "power play" into a headline. | Follow @CarlyHFierce
> Roche unchallenged at top of cancer sellers, but Celgene could fight Novartis for No. 2. Story
> Endo plans $1.75B stock sale to help cover Par buy. Article
> Teva shops for bigger Mylan stake in deal-forcing power play. Report
Pharma Marketing News
> Eyeing Xofigo growth, Bayer launches 'speak up' campaign in prostate cancer. News
> Big Pharma grapples with idiosyncrasies of orphan drug marketing. Story
> Novo Nordisk spins cycling into diabetes awareness with pro racing team. Article
> GSK's Flonase zooms to top of allergy category after DTC push. Item
> High-profile Huntington's disease film scores on social media, but where was pharma? More
Biotech Research News
> NCI matchmaker study explores uses of targeted drugs. Item
> Circadian rhythm research spotlights a possible cancer drug target. Report
> Aging researchers at McMaster flag role of a key protein in muscle loss. More
> Regenerative med researchers advance work on recycling discarded kidneys. Article
> Northeastern team solves mystery of recurring Lyme disease, offers a solution. Story
Diagnostics News
> Roche's Ventana teams up with Halozyme for pancreatic cancer companion Dx. Story
> Invitae slashes prices for full menu of genetic tests. Item
> LabCorp strikes liquid biopsy deal with Sysmex for cancer drug development. Article
> Merck teams up with NanoString to find genes that predict response to Keytruda. Story
> France's Labco sells out to Cinven for $1.3B after abandoning IPO. Report